Trade Agreement: WTO-AGP/NAFTA/AIT/Canada FTAs with
Peru/Colombia/Panama
Tendering Procedures: Generally only one firm has been invited
to bid
Attachment: None
Non-Competitive Procurement Strategy: Exclusive Rights
Comprehensive Land Claim Agreement: No
Vendor Name and Address:
BRUKER LTD.
555 Steeles Ave East
Milton Ontario
Canada
L9T1Y6
Nature of Requirements:
MALDI Biotyper-CM
6D063-132573/A
Tammy Kozak
Telephone No. - (204) 984-8825
Fax No. - (204) 983-7796
1. INTRODUCTION
Public Works and Government Services Canada (PWGSC), on behalf
of the National Microbiology Laboratory (NML), intends to
solicit a proposal and negotiate a contract with Bruker Ltd. In
Milton, Ontario for the supply and installation of a MALDI
Biotyper-CM.
2. BACKGROUND
The National Microbiology Laboratory (NML), a directorate of the
Infectious Disease and Emergency Preparedness Branch, Public
Health Agency of Canada (PHAC), is located in the Canadian
Science Centre for Human and Animal Health (CSCHAH) in Winnipeg,
Manitoba.
As Canada's leading public health infectious disease laboratory,
the NML is responsible for the identification, control and
prevention of infectious diseases. The NML's activities include
reference microbiology, support to epidemiology programs,
surveillance, emergency response, applied and discovery
research, and management of intellectual assets to improve
public health in Canada and internationally.
The Bioforensics Assay Development and Diagnostics (BADD) group
of the NML (PHAC) is responsible for the Government of Canada's
bioterrorism (BT) response capacity and is a part of the
National CBRNE team under mandate of the Federal Emergency
Management Act & the Federal Emergency Response Plan. The BADD
group performs diagnostic testing of all Category A- list
bioterrorism agents and leads the microbial forensics team for
trace-attribution of a biocrime. In the event of a
microbiological emergency, the BADD team is able to deploy to
the site of the event and test biological samples directly
on-site for infectious agents or toxins.
3. REQUIREMENT
The NML requires cutting-edge instruments for the detection and
identification of BT agents by their unique protein profile.
Specifically this instrument is for analysis of bacterial
cultures and diagnostic samples in our BSL-2 (biosafety level 2)
and BSL-3 containment laboratories, as well as the mobile
laboratory truck. A sensitive instrument for the analysis of
bacterial cultures is the Bruker Ltd. Microflex LT MALDI-TOF
(matrix-assisted laser desorption/ionization) mass spectrometer
(MS), which can fit on a laboratory bench-top. This instrument
produces unique bacterial protein spectra, allowing bacterial
identification against a database of known spectra. Furthermore,
it is compatible with currently-used bacterial identification
databases at the NML. Therefore, by acquiring the Bruker
MALDI-TOF Microflex LT the NML will increase its capacity for
rapid BT agent identification.
Also, this technology anticipates the coordination diagnostic
capabilities between the NML and the Canadian Laboratory
Response Network (CLRN), a group of Canadian public health
laboratories who are accredited for testing suspected BT agents.
This cooperation will expand the coordination and response
capability to microbiological emergencies across Canada.
4. MANDATORY PERFORMANCE SPECIFICATIONS
Any interested supplier must demonstrate by way of a statement
of capabilities that its system meets the following mandatory
requirements:
1) MALDI-TOF based mass spectrometry for analysis of bacterial
samples.
2) Due to the requirement for fitting into our unique CL-3
laboratory with limited space, must be a compact, bench-top
size instrument no larger than 25 inches x 30 inches x 50 inches
(height), and a reasonable weight (
